Literature DB >> 2021958

Comparison of lymphokine-activated killer activities between thymocytes and splenocytes in rats with brain tumors.

H Matsuura1, H Imaya.   

Abstract

We studied the lymphokine-activated killer (LAK) activity in splenocytes and thymocytes of rats with brain tumors chronologically from the early stage to the late stage, in order to clarify how much LAK activity would be developed at each stage. Simultaneously the natural killer (NK) activity in splenocytes, as one aspect of the host immunocompetence, was also determined. The splenic NK activity was significantly depressed in rats with brain tumors during the 2nd and 3rd weeks after tumor transplantation, as compared with normal controls. On the other hand, the splenocytes incubated with interleukin-2 showed the same killer activity in rats with brain tumors as in normal rats at all times. The LAK activity in thymocytes from rats with brain tumors was significantly higher than that of controls in the 1st and 2nd weeks and became equal to that of the controls during the 3rd week. The killer activity after incubation with interleukin-2 in thymocytes was superior to that in splenocytes throughout the experiment in both tumor-bearing rats and controls, which suggested that the precursor of LAK cells was not NK cells.

Entities:  

Mesh:

Year:  1991        PMID: 2021958     DOI: 10.1007/bf01742528

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

1.  Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells.

Authors:  S K Jacobs; G Melin; B Holcomb; C W Parham; P L Kornblith; E A Grimm
Journal:  Brain Res       Date:  1986-05-07       Impact factor: 3.252

2.  Comparison of in vitro glioma cell cytotoxicity of LAK cells from glioma patients and healthy subjects.

Authors:  V Bosnes; H Hirschberg
Journal:  J Neurosurg       Date:  1988-08       Impact factor: 5.115

3.  Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity.

Authors:  K Kuribayashi; S Gillis; D E Kern; C S Henney
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

4.  Induction of lymphokine-activated killer cells from rat thymocytes using recombinant human interleukin-2.

Authors:  H Imaya; H Matsuura; M Kudo; S Nakazawa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Regulation of natural killer cell function by glass-adherent cells in patients with primary intracranial malignancies.

Authors:  D P Braun; R D Penn; J E Harris
Journal:  Neurosurgery       Date:  1984-07       Impact factor: 4.654

6.  Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.

Authors:  K Shimizu; Y Okamoto; Y Miyao; M Yamada; Y Ushio; T Hayakawa; H Ikeda; H Mogami
Journal:  J Neurosurg       Date:  1987-04       Impact factor: 5.115

7.  In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.

Authors:  N Takai; R Tanaka; S Yoshida; N Hara; T Saito
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

8.  Prognostic significance of serum alpha 1-acid glycoprotein in patients with glioblastoma multiforme: a preliminary communication.

Authors:  H Matsuura; S Nakazawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-08       Impact factor: 10.154

9.  Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

Authors:  D Barba; S C Saris; C Holder; S A Rosenberg; E H Oldfield
Journal:  J Neurosurg       Date:  1989-02       Impact factor: 5.115

10.  Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Authors:  W H Brooks; M G Netsky; D E Normansell; D A Horwitz
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  1 in total

1.  Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.

Authors:  Timothy F Witham; Lorissa Villa; Tianbing Yang; Ian F Pollack; Hideho Okada; Paul D Robbins; William H Chambers
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.